Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nkarta, Inc. - Common Stock (NQ:NKTX)

1.966 -0.004 (-0.18%)
Streaming Delayed Price Updated: 1:21 PM EDT, Sep 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nkarta, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Why Shares of Nkarta Are Slumping Tuesday
The pharmaceutical stock dropped after announcing so-so clinical trial results. 
Via The Motley Fool
Analyst Expectations for Nkarta's Future
 
Via Benzinga
Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia
From Nkarta, Inc.
Via GlobeNewswire
Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX101 NK Cell Therapy Program
Call scheduled for Tuesday, June 27, 2023 at 8:00 a.m. ET 
From Nkarta, Inc.
Via GlobeNewswire
SVB Leerink Picks This Well-Positioned NK Cell-Focused Stock, Sees 117% Upside
 
Via Benzinga
Nkarta Presents NKX019 Clinical Data at the European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma
From Nkarta, Inc.
Via GlobeNewswire
Nkarta Reports First Quarter 2023 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
7 Stocks With Promising Upside Potential for 100% Returns
If you still want to gamble even during this market environment, these are the stocks with 100% upside potential. 
Via InvestorPlace
Nkarta Presents Preclinical Data Exploring Gene Knockout Strategies and Combination Agents with NK Cell-Based Therapies at the 2023 AACR Annual Meeting
From Nkarta, Inc.
Via GlobeNewswire
3 Biotech Stocks to Watch for Potential Breakthroughs
These biotech stocks have significant upside and realistic breakthrough chances in the current and distant future. 
Via InvestorPlace
NVIDIA To Rally Around 19%? Here Are 10 Other Analyst Forecasts For Friday
Wells Fargo raised the price target for Warner Bros. Discovery, Inc. (NASDAQ: WBD) from $13 to $20. Wells Fargo analyst Steven Cahall upgraded the stock from Equal-Weight to Overweight. Warner Bros.... 
Via Benzinga
Nkarta Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
EXCLUSIVE: Top 10 Searched Tickers On Benzinga Pro In December 2022: Where Do Tesla, Apple, AMC Rank?
Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 22, 2022
 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  During Thursday's trading, 138 companies set new 52-week lows. 
Via Benzinga
What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers
Since Robert Hooke discovered cells in 1665 and Theodor Schwann proposed the classical cell theory in 1839, the cell therapy industry has grown by leaps and bounds. 
Via TheNewswire.com
What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers
By Ernest Dela Aglanu, Benzinga 
Via News Direct
VF Corp, Verve Therapeutics And Some Other Big Stocks Moving Lower On Monday
U.S. stocks traded lower, with the Dow Jones dropping over 200 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Why Nkarta Stock (NKTX) Is Volatile During Monday's Session?
Nkarta Inc (NASDAQ: NKTX) shares are trading lower by 5.82% to $8.09, reversing after trading higher during the pre-market session, after the company announced updated data from its Phase 1 dose... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
The biggest pre-market stock movers for Monday include many Chinese shares that traders will want to keep an eye on today! 
Via InvestorPlace
Nkarta Announces Updated Clinical Data on Anti-CD19 Allogeneic CAR-NK Cell Therapy NKX019 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
From Nkarta, Inc.
Via GlobeNewswire
Nkarta Reports Third Quarter 2022 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
Nkarta Presents Data Supporting Engineered NK Cell Based Combination Therapies and Next Generation Commercial-Scale Manufacturing Platform at SITC 37th Annual Meeting
From Nkarta, Inc.
Via GlobeNewswire
What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers
Since Robert Hooke discovered cells in 1665 and Theodor Schwann proposed the classical cell theory in 1839, the cell therapy industry has grown by leaps and bounds. 
Via Benzinga
7 Unknown Biotech Stocks That Could Rocket in 2023
Unknown biotech stocks that are poised for a big rally in 2023. Emerging biotech companies with a promising clinical pipeline. 
Via InvestorPlace
Cowen Slashes Price Target On This Stock By Over 78%; Also Check Out Some Other Big PT Changes
Cowen & Co. cut the price target for The RealReal, Inc. (NASDAQ: REAL) from $14 to $3. RealReal shares fell 0.7% to $3.1388 in pre-market trading. 
Via Benzinga
Will Another Enlivex Innovation Break The Glass Ceiling For Solid Tumor Treatments?
Cell therapy — the use of stem cells and various engineered immune cells to target difficult-to-treat diseases like cancer and autoimmune conditions — has arguably been one of the big breakthroughs in... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 28, 2022
  
Via Benzinga
Positive Clinical Results Put Nkarta Stock on the Fast Track
NKTX stock is a fast mover, and a recent share-price bump came in the wake of exciting data from a "killer cell" anti-cancer research program. 
Via InvestorPlace
Executives Buy More Than $32M Of 3 Stocks
Although US stocks closed sharply lower on Friday, there were a few notable insider trades. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.